EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Real‐world experience of tyrosine kinase inhibitors in children, adolescents and adults with relapsed or refractory bone tumours: A Canadian Sarcoma Research and Clinical Collaboration ( CanSaRCC ) study

Hagit Peretz Soroka, Tushar Vora, Jonathan Noujaim, Nicolas Marcoux, Sarah Cohen-Gogo, Thierry Alcindor, Caroline Holloway, Caroline Rodrigues, Hatim Karachiwala, Saima Alvi, Ursula Lee, Sylvia Cheng und 7 weitere

Cancer Medicine · 2023-09 · 12 (18) · 18872-18881

DOI: 10.1002/cam4.6515 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Medicine, online erschienen am 19.09.2023. Verfasst von Hagit Peretz Soroka und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Bone Neoplasms, Sarcoma, Sarcoma, Ewing, Osteosarcoma. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

We conducted a retrospective multi‐centre study to assess the real‐world outcome of regorafenib (REGO) and cabozantinib (CABO) in recurrent/refractory bone tumours (BTs) including osteosarcoma (OST), Ewing sarcoma (EWS) and chondrosarcoma (CS)/extra‐skeletal mesenchymal CS (ESMC).

Methods

After regulatory approval, data from patients with recurrent BT (11 institutions) were extracted from CanSaRCC (Canadian Sarcoma Research and Clinical Collaboration) database. Patient characteristics, treatment and outcomes were collected. Progression‐free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method.

Results

From July 2018 to May 2022, 66 patients received REGO or CABO; 39 OST, 18 EWS, 4 CS and 5 ESMC. Median age was 27.8 years (range 12–76); median starting dose was 60 mg for CABO ( n = 37, range 40–60) and 120 mg for REGO ( n = 29, range 40–160). Twenty‐eight (42.4%) patients required dose reduction: hand‐foot syndrome 7 (10.6%), nausea/vomiting 1 (1.5%), diarrhoea 1 (1.5%), 2 elevated LFTs (3%), elevated bilirubin 1 (1.5%) and mucositis 1 (1.5%). The median OS for patients with OST, EWS, CS and ESMC was 8.5 months ( n = 39, 95% CI 7–13.1); 13.4 months ( n = 18, 95% CI 3.4–27.2), 8.1 ( n = 4, 95% CI 4.1–9.3) and 18.2 ( n = 5, 95% CI (10.4–na), respectively. Median PFS for OST, EWS, CS and ECMS was 3.5 ( n = 39, 95% CI 2.8–5), 3.9 ( n = 18, 95% CI 2.1–5.9), 5.53 ( n = 4. 95% CI 2.13–NA) and 11.4 ( n = 5, 95% CI 1.83–14.7), respectively. Age, line of therapy, REGO versus CABO, or time from diagnosis to initiation of TKI were not associated with PFS on univariable analysis.

Conclusion

Our real‐world data show that TKIs have meaningful activity in recurrent BT with acceptable toxicities when started at modified dosing. Inclusion of TKIs in earlier lines of treatment and/or maintenance therapy could be questions for future research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone NeoplasmsSarcomaSarcoma, EwingOsteosarcomaChondrosarcomaSoft Tissue NeoplasmsHumansAdultChildAdolescentYoung AdultMiddle AgedAgedTyrosine Kinase InhibitorsNeoplasm Recurrence, LocalCanadaRetrospective StudiesPhenylurea CompoundsPyridines

Stichwörter der Autor:innen

CanSaRCCEwing sarcomacabozantanibchondrosarcomaosteosarcomaregorafenib

Substanzen

Tyrosine Kinase InhibitorsregorafenibPhenylurea CompoundsPyridines

Autor:innen und Institutionen

  • Division of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
  • Division of Hematology/Oncology, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
  • Division of Medical Oncology, Hôpital Maisonneuve Rosemont, University of Montreal, Montreal, Quebec, Canada.
  • Division of Hematology-Oncology, Centre Hospitalier Universitaire de Québec, Quebec, Canada.
  • Division of Medical Oncology, McGill University Health Centre, Montreal, Quebec, Canada.
  • Division of Radiation Oncology, BC Cancer, University of British Columbia, Vancouver, British Columbia, Canada.

ORCID-Profile: Sapna Oberoi, Abha A Gupta

Zitieren

APA

Peretz Soroka, H., Vora, T., Noujaim, J., Marcoux, N., Cohen-Gogo, S., Alcindor, T., Holloway, C., Rodrigues, C., Karachiwala, H., Alvi, S., Lee, U., Cheng, S., Banerji, S., Oberoi, S., Feng, X., Smrke, A., Simmons, C., Razak, A. A., & Gupta, A. A. (2023). Real‐world experience of tyrosine kinase inhibitors in children, adolescents and adults with relapsed or refractory bone tumours: A Canadian Sarcoma Research and Clinical Collaboration ( CanSaRCC ) study. Cancer Medicine, 12(18), 18872-18881. https://doi.org/10.1002/cam4.6515

Vancouver

Peretz Soroka H, Vora T, Noujaim J, Marcoux N, Cohen-Gogo S, Alcindor T, et al. Real‐world experience of tyrosine kinase inhibitors in children, adolescents and adults with relapsed or refractory bone tumours: A Canadian Sarcoma Research and Clinical Collaboration ( CanSaRCC ) study. Cancer Medicine. 2023;12(18):18872-18881. doi:10.1002/cam4.6515

BibTeX
@article{PeretzSoroka2023,
  author = {Peretz Soroka, Hagit and Vora, Tushar and Noujaim, Jonathan and Marcoux, Nicolas and Cohen-Gogo, Sarah and Alcindor, Thierry and Holloway, Caroline and Rodrigues, Caroline and Karachiwala, Hatim and Alvi, Saima and Lee, Ursula and Cheng, Sylvia and Banerji, Shantanu and Oberoi, Sapna and Feng, Xiaolan and Smrke, Alannah and Simmons, Christine and Razak, Albiruni Abdul and Gupta, Abha A},
  title = {Real‐world experience of tyrosine kinase inhibitors in children, adolescents and adults with relapsed or refractory bone tumours: A Canadian Sarcoma Research and Clinical Collaboration ( CanSaRCC ) study},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {18},
  pages = {18872--18881},
  doi = {10.1002/cam4.6515}
}
Kostenlos starten →